interferon
Enable an AI agent to identify an interferon material, assess its integrity and context-dependent biological activity, and determine which handling, measurement or use actions are justified.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
Researched by: Codex + Grok
Purpose and description
Enable an AI agent to identify an interferon material, assess its integrity and context-dependent biological activity, and determine which handling, measurement or use actions are justified.
Interferons are an inducible family of secreted class-II helical cytokines that bind type-specific heterodimeric receptors (IFNAR, IFNGR, or IFNLR) to activate JAK-STAT signalling and interferon-stimulated genes, thereby establishing an antiviral state and modulating innate and adaptive immunity.
It can be Classify an interferon sample to the most specific identity supported by evidence.; Select identity, concentration and functional assays suited to its subtype and matrix.; Compare preparations when molecular form, calibration and response conditions are compatible.; Plan aliquoting, dilution, storage or reconstitution using preparation-specific instructions.; Assess whether an experimental response can reasonably be attributed to the interferon.; Flag a preparation for retesting, restricted use or rejection when evidence fails intended-use criteria..
Distinguishing features
Require protein-level identity evidence to distinguish interferon material from a gene, transcript or downstream interferon-response signature.
Resolve family, subtype and species rather than treating the word interferon as one chemically interchangeable substance.
Distinguish interferon from other cytokines using sequence or validated molecular recognition evidence; an antiviral response alone is insufficient identification.
Separate unmodified interferon from pegylated, fused, tagged or otherwise engineered forms using molecular-form evidence.
Distinguish detected interferon protein from demonstrated biological activity by recording identity or abundance assays separately from functional assays.
Scope
+ Interferon family, subtype, species of origin and sequence identity
+ Endogenous, isolated and recombinant interferon materials, including modified forms
+ Interferon concentration, purity, integrity and assay-specific potency
+ Receptor compatibility and biological response in a specified test system
+ Preparation composition, storage history and fitness for an intended material use
- Interferon genes, transcripts, vectors and their expression-control mechanisms
- Interferon receptors as independently modelled molecular entities
- Whole immune pathways, infections and interferon-associated diseases
- Patient diagnosis, treatment selection, dosing and clinical monitoring
- Finished medicinal-product authorization, prescribing information and distribution
- Assay instruments, laboratory facilities and general experimental protocols
Characteristics
- Interferon classification
- Type I, type II, type III, unresolved or other supported classification; named subtype Prevents family-level labels from concealing biologically relevant differences.
- Species and sequence identity
- Source organism, protein accession and version, mature sequence and documented variants Anchors identity and informs whether evidence from a particular biological system applies.
- Molecular modification
- Unmodified, glycosylated, pegylated, fusion, tagged, sequence-engineered, mixed or unresolved; modification details Makes differences between native proteins and engineered preparations explicit.
- Production origin
- Biological source or expression host, purification record and sample or lot identifier Connects material identity and possible impurities to its actual origin.
- Interferon concentration
- Mass per volume or molar concentration, with method, matrix, uncertainty and molecular-mass basis Supports dilution and exposure calculations without substituting concentration for potency.
- Functional potency
- IU/mL, IU/mg or explicitly defined assay units, with reference material, endpoint and test system Allows activity comparisons only where calibration and assay context support them.
- Molecular integrity
- Intact, fragmented, aggregated, chemically altered, mixed or unassessed; supporting measurements Supports assessment of degradation and suitability for further use.
- Purity and interfering components
- Method-defined purity percentage and measured concentrations of relevant impurities or other cytokines Helps distinguish interferon effects from preparation or matrix effects.
- Responsive biological system
- Species, cell or tissue model, receptor evidence, exposure conditions and response endpoint Keeps activity claims tied to systems in which they were established.
- Preparation condition
- Formulation, physical form, temperature history, time since reconstitution and freeze-thaw history Provides evidence for applying preparation-specific handling and retesting rules.
Also called
Where this came from
wikidata · CC0 1.0
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 6 bundles · 11 layers · 18 findings · 28 questions.
Interferon identity Establish which interferon the record describes and how precisely it is identified.
Interferon is a family-level name; recognition and comparison require finer molecular distinctions.
Family and subtype
Resolve the recorded name to a supported interferon classification.
Supported interferon assignment
Record the family, subtype and evidence supporting assignment, retaining unresolved or mixed identities explicitly.
- Which interferon family and subtype does the name denote in this record? definition
- What protein-level evidence supports that assignment rather than merely showing an interferon-associated response? measurement
Sequence and molecular form
Distinguish species-specific proteins and engineered forms within the registry entry.
Identified protein form
Record source species, mature sequence and modifications without treating a subtype label as a complete material identity.
- Which organism, sequence reference and mature protein boundaries identify this interferon? provenance
- Which substitutions, glycans, conjugates, fusion partners or tags distinguish this form from its reference protein? definition
Origin and composition Describe how the interferon entered the sample and what accompanies it.
An endogenous sample, purified protein and formulated reagent require different interpretations of identity and observed effects.
Biological and production origin
Connect the material to its biological source or production process.
Traceable interferon material
Record whether the material was sampled endogenously, isolated or produced recombinantly, with traceability to the actual preparation.
- Was this interferon collected from a biological specimen, purified from a producer system or expressed recombinantly? provenance
- Which sample, expression-host, purification and lot records establish the origin of this material? provenance
Matrix and co-components
Identify the surrounding matrix and components relevant to measurement or use.
Attributable preparation composition
Record interferon mixtures, carrier proteins, excipients and measured impurities that may alter interpretation of the preparation.
- Does the preparation contain one identified interferon, several interferons or an unresolved mixture? boundary
- Which matrix components, other cytokines or production impurities require measurement or controls before attributing a response to interferon? measurement
Amount and functional potency Keep measurements of interferon abundance distinct from calibrated biological activity.
Agents need both quantity and functional evidence to compare preparations or calculate experimental exposures responsibly.
Protein quantity
Establish what an abundance assay measures and how its result is expressed.
Interpretable interferon concentration
Record the measured analyte, assay specificity, concentration basis and limits of detection or quantification.
- Does the reported concentration measure the intended interferon specifically, a cross-reactive group or total preparation protein? measurement
- What units, calibration, matrix corrections and uncertainty support the concentration value? measurement
Activity calibration
Make potency values interpretable through their assay and reference preparation.
Traceable functional potency
Record the activity endpoint and calibration reference. WHO's interferon-alpha2b standardization work illustrates the need to identify the reference used for potency assignment: [WHO interferon-alpha2b standardization study](https://www.who.int/publications/m/item/WHOBS2020.2389).
- Which cell system, response endpoint, exposure period and reference preparation define the reported potency? measurement
- What evidence permits comparing these units or converting activity to mass for this specific interferon preparation? boundary
Receptor-dependent response Relate an identified interferon to responsive systems and observed biological effects.
A potency value or response observed in one system does not by itself establish activity in another.
Target-system compatibility
Establish whether the intended biological system can respond to this interferon form.
Supported response compatibility
Record receptor requirements and evidence of responsiveness for the actual species and cell or tissue system.
- Which receptor complex is relevant to this interferon, and what evidence establishes its availability and function in the target system? definition
- Has responsiveness to this species-specific or engineered interferon been established in the intended test system? boundary
Response attribution
Separate measured interferon effects from proxies, confounders and unsupported extrapolation.
Bounded biological effect
Record the observed response, exposure conditions and controls needed to interpret its relation to interferon.
- Which endpoint was measured, at what concentration and duration, and with what viability and matrix controls? measurement
- What neutralization, receptor-blocking or other suitable control supports attribution of the response to this interferon? measurement
Integrity and use readiness Assess the current material condition and evidence needed before a proposed handling or experimental action.
An identified interferon preparation may still lack the integrity, activity or documentation required for its intended use.
Stability and handling history
Connect observed integrity to formulation and actual handling conditions.
Current interferon condition
Record structural and functional assessments alongside storage, reconstitution and freeze-thaw history.
- What evidence establishes current integrity and retained activity, including any aggregation or fragmentation? measurement
- Which storage conditions, elapsed times and handling excursions occurred relative to instructions validated for this preparation? provenance
Action eligibility
Determine whether evidence supports a specific material action and identify decisions owned elsewhere.
Justified interferon use
Tie preparation selection, dilution, retesting or rejection to stated experimental requirements; refer patient-use decisions to the relevant medicinal-product and clinical models.
- Does the preparation meet the identity, potency, purity and condition requirements for the proposed experiment or handling step? action
- Which preparation-specific instructions justify proceeding, and what missing evidence requires retesting or referral to another model? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Kinds and varieties
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Type I interferons (human IFN-α subtypes, IFN-β, IFN-ε, IFN-κ, IFN-ω; IFN-τ in ruminants)
- Type II interferon (IFN-γ, the sole member)
- Type III interferons (IFN-λ1/IL-29, IFN-λ2/IL-28A, IFN-λ3/IL-28B, IFN-λ4)
- Recombinant interferon alfa products (interferon alfa-2a, interferon alfa-2b, interferon alfacon-1)
- Pegylated and other long-acting interferon alfa (peginterferon alfa-2a/2b, ropeginterferon alfa-2b)
- Recombinant interferon beta used as multiple-sclerosis disease-modifying therapy (IFN-β-1a, IFN-β-1b)
- Recombinant interferon gamma-1b
- Veterinary interferon omega (notably feline IFN-ω)
- Which of these kinds and varieties hold for the sense of interferon this model covers, and on what evidence? provenance
Identifiers and schemes
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Wikidata - Q58731 - Item for the interferon class as a whole; individual ligands and products have their own items.
- MeSH - D007378 - Heading Interferons; narrower headings exist for interferon type I, interferon-gamma, and named products.
- ATC - L03AB* - Immunostimulants, interferons: e.g. L03AB04 interferon alfa-2a, L03AB05 interferon alfa-2b, L03AB07 interferon beta-1a, L03AB08 interferon beta-1b, L03AB03 interferon gamma, L03AB11 peginterferon alfa-2a.
- WHO INN - interferon alfa-* | interferon beta-* | interferon gamma-* | peginterferon alfa-* | ropeginterferon alfa-* - INN spelling uses 'alfa' for alpha ligands; the stem names the ligand type and, for recombinant products, the subtype (2a, 2b, 1a, 1b).
- HGNC gene symbol - IFNA1-IFNA21, IFNB1, IFNE, IFNK, IFNW1, IFNG, IFNL1-IFNL4 - Human gene nomenclature for the secreted ligands; IFNAR1/IFNAR2, IFNGR1/IFNGR2, IFNLR1 name the receptors, not the ligands.
- NCBI Gene - 3440 (IFNA2); 3456 (IFNB1); 3458 (IFNG) - Representative human gene IDs for the three ligands most often encountered as medicines or assays.
- UniProt - P01563 (IFNA2_HUMAN); P01574 (IFNB_HUMAN); P01579 (IFNG_HUMAN) - Reviewed protein entries for the principal human therapeutic ligands.
- Which of these identifiers and schemes hold for the sense of interferon this model covers, and on what evidence? provenance
Standards and regulation
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- WHO International Standards for interferons, held by NIBSC, define potency in International Units for type I, II and III ligands and are the reference for bioassays.
- WHO International Nonproprietary Names programme assigns the interferon/peginterferon INNs used on labels.
- European Pharmacopoeia (EDQM) monographs specify identity, glycosylation-related quality attributes, impurities and IU potency for interferon concentrated solutions and finished products.
- United States Pharmacopeia and FDA biologics licensing (BLA under the PHS Act) govern US interferon medicinal products; products are prescription biologics, not chemically synthesised small-molecule drugs.
- EMA product information and CHMP scientific guidelines on similar biological medicinal products containing interferons cover originator and biosimilar interferon beta and alfa.
- ICH Q5A/Q5C/Q6B quality guidelines apply to interferon manufacture, stability and specification setting as recombinant proteins.
- Which of these standards and regulation hold for the sense of interferon this model covers, and on what evidence? provenance
Real-world use
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Injectable disease-modifying therapy in relapsing multiple sclerosis (IFN-β-1a intramuscular or subcutaneous; IFN-β-1b subcutaneous).
- Historical and remaining treatment of chronic hepatitis B, and formerly chronic hepatitis C, as (peg)interferon alfa, often with ribavirin before direct-acting antivirals.
- Oncology and haematology: hairy-cell leukaemia, selected myeloproliferative neoplasms (including ropeginterferon alfa-2b in polycythaemia vera), melanoma and AIDS-related Kaposi sarcoma.
- IFN-γ-1b as adjunctive therapy in chronic granulomatous disease and delay of disease in malignant osteopetrosis.
- IFN-γ release assays (e.g. QuantiFERON) as blood tests for Mycobacterium tuberculosis infection.
- Laboratory reagents and antiviral bioassays (cytopathic-effect reduction) to quantify IFN potency and to phenotype viral IFN antagonists.
- Endogenous type I IFN as a clinical biomarker in SLE, COVID-19 and genetic interferonopathies.
- Which of these real-world use hold for the sense of interferon this model covers, and on what evidence? provenance
Typical measurements
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Antiviral specific activity of purified recombinant IFN-α2 - about 1e8-3e8 - IU/mg
- Circulating IFN-α in healthy plasma (immunoassay, highly assay-dependent) - often below limit of detection to about 5-20 - pg/mL
- Peginterferon alfa-2a adult dose in viral hepatitis regimens - 180 - µg/week
- IFN-β-1a (high-dose subcutaneous product) maintenance dose - 22-44 - µg three times weekly
- QuantiFERON-TB Gold IFN-γ positivity cutoff (nil-subtracted) - 0.35 - IU/mL
- Neutralising anti-IFN antibody titre (product-specific; clinically relevant thresholds vary) - often considered material above ~20-100 - neutralising units or tenfold-reduction units
- Which of these typical measurements hold for the sense of interferon this model covers, and on what evidence? provenance
Failure modes and hazards
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Treatment-limiting flu-like syndrome, cytopenias, transaminase rises and injection-site reactions, including necrosis with some IFN-β-1b presentations.
- IFN-α neuropsychiatric toxicity, including depression and suicidal behaviour, requiring pre-treatment risk assessment.
- Induction or unmasking of autoimmunity, especially thyroiditis, and worsening of some pre-existing autoimmune diseases.
- Neutralising anti-drug antibodies that abolish bioactivity, well documented for IFN-β in multiple sclerosis.
- Type I interferonopathies (e.g. Aicardi-Goutières syndrome, SAVI) from excessive IFN signalling rather than from the ligand as a medicine.
- Neutralising autoantibodies against type I IFN associated with life-threatening viral disease, including a subset of severe COVID-19.
- Primary non-response in former HCV regimens associated with IFNL3 (IL28B) genotype and with viral IFN-evasion proteins.
- Over-attribution of a raised 'interferon signature' to circulating IFN protein: ISG transcripts can be high when ligand is undetectable.
- Which of these failure modes and hazards hold for the sense of interferon this model covers, and on what evidence? provenance
Regional variation
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- INN and US/EU labelling use 'interferon alfa'; scientific and gene nomenclature use 'alpha'.
- Peginterferon alfa remains more visible in hepatitis B practice, and in some lower-resource hepatitis C settings, than in high-income HCV care now dominated by direct-acting antivirals.
- IFN-τ is a pregnancy-recognition factor in ruminants and is not a human therapeutic class.
- Recombinant feline interferon omega has been authorised in some veterinary markets (notably Europe and Japan) and is not a routine US human or companion-animal standard.
- National brand sets differ (e.g. Avonex/Rebif/Betaferon-Betaseron for IFN-β) and biosimilar interferon beta availability is uneven by region.
- Clinical testing for anti-type I IFN autoantibodies is still concentrated in specialist centres and is not uniformly available.
- Which of these regional variation hold for the sense of interferon this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Reported by the breadth pass; each item needs checking against its source before it becomes normative.
- Interferon regulatory factors (IRF3, IRF7, and paralogues) - IRFs are intracellular transcription factors that drive IFN-gene transcription; interferons are the secreted ligands. Separate by gene family, subcellular localisation, and whether the protein binds IFNAR/IFNGR/IFNLR.
- Interferon-stimulated gene products (MxA/Mx1, OAS, PKR/EIF2AK2, ISG15) - These are effectors induced by IFN signalling, not IFN itself. Separate by whether the analyte is the ligand (or its receptor) versus a downstream ISG protein or transcript.
- Interleukin-10 family cytokines (IL-10, IL-22, IL-26) - IFN-λ shares the IL-10Rβ chain but pairs it with IFNLR1 and induces an ISG programme; IL-10 uses IL-10Rα/IL-10Rβ and does not. Separate by receptor heterodimer occupancy and STAT1/ISGF3-dependent ISG induction.
- Other inflammatory cytokines (IL-1, IL-6, TNF) - They can mimic fever and acute-phase effects of IFN therapy but do not signal through IFNAR/IFNGR/IFNLR. Separate by receptor usage and a canonical ISG signature (e.g. MX1, IFIT1, RSAD2).
- Type I versus type II versus type III interferon - Not different substances in the loose sense, but routinely confused in lab orders and papers. Separate by ligand identity plus receptor: IFNAR1/2 (type I; historically acid-stable), IFNGR1/2 (type II; historically acid-labile), IFNLR1/IL10RB (type III; epithelial-biased).
- Which of these neighbouring kinds and how to tell them apart hold for the sense of interferon this model covers, and on what evidence? provenance
Sources
- Virus interference. I. The interferon - Original demonstration that a secreted, virus-induced factor (interferon) confers interference, which is the founding definition of the class.
- Interferons, interferon-like cytokines, and their receptors - Receptor-based classification into types I-III, ligand repertoire, JAK-STAT signalling, and the distinction from interferon-like cytokines.
- Shared and Distinct Functions of Type I and Type III Interferons - Functional split between IFNAR- and IFNLR-using ligands, tissue restriction of type III responses, and ISG biology used to separate types in practice.
- ATC/DDD Index: L03AB Interferons - WHO anatomic-therapeutic classification of interferon medicinal products (alfa, beta, gamma, pegylated forms) as used in formularies.
- MeSH: Interferons (D007378) - Controlled vocabulary placing interferons as a cytokine class with type I/II/III children and therapeutic headings.
- European Pharmacopoeia monographs on interferon concentrated solutions and products - Pharmacopoeial identity, purity and potency of therapeutic interferons, including assay in International Units against WHO reference preparations.
What the second pass must settle
- Does the registry intend interferon to cover all species and engineered derivatives, or a narrower set of materials?
- Which authoritative nomenclature and sequence references should resolve interferon subtype names and historical aliases across species?
- Which potency standards and assay-comparability rules are applicable to each included interferon subtype and molecular form?
- What preparation-specific stability evidence and acceptance criteria should govern storage excursions, reconstitution and freeze-thaw exposure?
- Where should the catalogue place the ownership boundary between an interferon protein, a modified interferon conjugate and a finished medicinal product?